Jecure Therapeutics

About Jecure Therapeutics

Jecure Therapeutics operated as a biotechnology firm concentrated on creating new treatments for non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company was founded in 2015, with initial seed financing from venture capital firm Versant Ventures. Its scientific foundation was built upon over a decade of research from the lab of Dr. Ariel Feldstein, a prominent physician-scientist in hepatology and the Division Chief of Gastroenterology at the University of California, San Diego (UCSD). Dr. Feldstein's work on the biochemical pathways of cell death and inflammation in the liver provided the scientific basis for Jecure's discovery platform. The management team included CEO Jeffrey Stafford and CSO James Veal, who had a 20-year history of collaboration, including co-inventing multiple commercial drugs and previously leading another Versant-backed startup, Quanticel Pharmaceuticals, to a successful acquisition by Celgene.

The company's primary business was drug discovery, specifically targeting the NLRP3 inflammasome, a protein complex known to be a key driver of liver inflammation and fibrosis. Jecure leveraged a proprietary platform developed at UCSD that included advanced models for target identification, validation, and in-vivo screening, aiming to create first-in-class small molecule inhibitors. This focus on novel biology was intended to provide a competitive advantage in the crowded NASH market, which is projected to become a multi-billion dollar industry due to rising rates of obesity and diabetes. The business model was centered on advancing these preclinical assets to a point where they would be attractive for acquisition or partnership with a larger pharmaceutical company. This strategy proved successful when, in November 2018, less than two years after its formal launch and Series A funding, Jecure was acquired by Genentech, a subsidiary of Roche. The acquisition gave Genentech full rights to Jecure's portfolio of preclinical NLRP3 inhibitors, marking a strategic entry for the pharmaceutical giant into the competitive NASH therapeutic space.

Jecure's key achievement was its rapid progression from inception to a strategic exit. The company officially launched in February 2017 with a $20 million Series A funding round solely from Versant Ventures. This funding was intended to advance its portfolio of NLRP3 inhibitors, with the goal of naming its first development candidate by late 2017. The company's work culminated in the acquisition by Genentech, which highlighted the value of its focused research on the NLRP3 pathway for treating a range of inflammatory diseases beyond NASH, including gout and inflammatory bowel disease.